Bacterial Minicells for Targeted Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering functional nucleic acids to mammalian cells, such as liposome-based transfection and viral vectors, face issues like transient inhibition, instability, safety concerns, and limited capacity, which hinder effective treatment of drug resistance in cancer and HIV by failing to consistently target and overcome mechanisms like P-glycoprotein and Bcl-2 overexpression.
Innovation Solution
The use of intact minicells that contain functional nucleic acids or plasmids encoding these molecules, which are engineered to target specific proteins contributing to drug resistance and apoptosis resistance, allowing for targeted delivery and expression within mammalian cells, potentially combined with chemotherapeutic drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If liposome-based transfection methods are used to deliver exogenously produced nucleic acids, then delivery of functional nucleic acids is achieved, but the inhibition is only transient and liposomes are unstable in vivo
Solution Approach 1:
The patent uses viral vectors as intermediary carriers to deliver plasmid DNA that encodes functional nucleic acids. The viral vector mediates the delivery process, allowing the plasmid to enter mammalian cells and express the functional nucleic acid continuously, thereby achieving both prolonged inhibition and in vivo stability that neither liposomes nor direct nucleic acid delivery can accomplish alone.
Solution Approach 2:
The patent employs viral vectors to deliver plasmid DNA that encodes the functional nucleic acid before the actual therapeutic action is needed. This preliminary delivery allows the cell to produce the functional nucleic acid endogenously, ensuring continuous and stable expression over time, thus resolving the transient nature of exogenous nucleic acid delivery.
2Duration of action of moving object
If viral vectors are used to deliver plasmids encoding functional nucleic acids, then continuous production of functional nucleic acids is achieved, but serious safety concerns arise including recombination with wild-type viruses, insertional and oncogenic potential, and immunosuppression
Solution Approach 1:
The patent extracts and eliminates the harmful components associated with viral vectors while retaining the beneficial gene delivery capability. By using plasmid DNA delivered by non-viral methods (such as liposomes or naked DNA), the invention removes the risks of viral recombination, insertional mutagenesis, and immunosuppression, while still achieving continuous production of functional nucleic acids through endogenous expression.
Solution Approach 2:
The patent uses plasmid DNA as a disposable, non-integrating genetic element that can be delivered and expressed transiently or continuously without permanent genomic integration. This approach avoids the long-term safety concerns of viral vectors while maintaining the ability to produce functional nucleic acids, effectively using a simpler, safer alternative that can be replenished as needed.
3Reliability
If high concentrations of chemotherapeutic drugs are used to overcome drug resistance in cancer cells, then drug resistance is overcome, but toxicity increases
Solution Approach 1:
The patent replaces the mechanical/chemical force of high-dose chemotherapy with a biological mechanism: using functional nucleic acids (such as antisense oligonucleotides, ribozymes, or siRNA) to specifically target and inhibit the expression of drug resistance proteins like P-glycoprotein. This substitution allows overcoming drug resistance through molecular interference rather than brute-force high-dose drug administration, thereby reducing toxicity while maintaining effectiveness.
Solution Approach 2:
The patent applies local quality by using functional nucleic acids that specifically target only the drug resistance proteins in cancer cells, rather than affecting all cells non-specifically. This targeted approach allows the therapeutic action to be concentrated where needed (in the cancer cells expressing resistance proteins) while sparing normal cells, thus overcoming resistance without proportionally increasing systemic toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a safe, stable, and effective means to overcome drug resistance and promote apoptosis in cancer cells by delivering functional nucleic acids directly into target cells, reducing the need for high drug concentrations and minimizing toxicity, as demonstrated by successful treatment of drug-resistant cancer xenografts in nude mice.
Implementation Method 1
bringing the minicell into contact with a target mammalian cell, such that the mammalian cell engulfs the minicell
Data Source
AI summary
Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.